

ORAL PRESENTATION

Open Access

Quantitative MR-neurographic parameters can determine and specify nerve injury in amyloid related polyneuropathy

Jennifer Kollmer^{1*}, Ernst Hund², Stefan Schönland³, Ute Hegenbart³, Christoph Kimmich³, Arnt Kristen⁴, Martin Bendszus¹, Mirko Pham¹

From First European Congress on Hereditary ATTR amyloidosis
Paris, France. 2-3 November 2015

Background

Hereditary transthyretin-familial-amyloid-polyneuropathy (TTR-FAP) usually manifests with a rapidly progressive, distally-symmetric polyneuropathy [Plante-Bordeneuve, V. and G. Said, *Lancet Neurol*, 2011; Hund et al, *Neurology* 2001]. Recently, we were able to show that nerve-injury in TTR-FAP is detectable in-vivo by applying high-resolution MR-Neurography [Kollmer et al, *Brain* 2015]. The aim of the current study is to further quantify nerve-lesions at thigh-level where nerve-injury has been shown to be strongest, and to determine the ability of two quantitative parameters to clearly differentiate between symptomatic TTR-FAP, asymptomatic gene-carriers and healthy volunteers.

Methods

20 patients with confirmed mutations in the TTR-gene (13 with symptomatic TTR-FAP, 7 asymptomatic gene-carriers), and 40 age/gender-matched healthy volunteers were prospectively included and classified according to neurological and electrophysiological findings. MR-Neurography with high structural resolution was performed on a 3T-MR-scanner (Magnetom/TIM-TRIO/Siemens): 1) T2-TSE-fs (TR/TE 5970/55ms, voxel-size 0.4x0.3x3.5mm³); 2) Dual-echo-TSE-fs (TR 5210ms, TE1/TE2 12/73ms, voxel-size 0.4x0.3x3.5 mm³).

Manual voxel-wise segmentation of the sciatic/tibial/common-peroneal nerve with subsequent fully-automatic classification as nerve-lesion-voxels was performed on each axial imaging slice (280/subject). The apparent-T2-relaxation-time (T2app) and proton-spin-density as

distinct and quantifiable parameters that measure micro-structural nerve-tissue-composition in-vivo [Heiland et al, *Neurosci Lett*. 2002] were then calculated for all nerve-lesion-voxels.

Results

One-way-ANOVA and post-hoc comparisons showed that proton-spin-density was highest in symptomatic TTR-FAP (549.97±35.78), decreased significantly in asymptomatic gene-carriers (406.09±28.22; p=0.002), and further decreased significantly in controls (286.56±10.04; p<0.0001 vs. symptomatic TTR-FAP and vs. asymptomatic gene-carriers (p=0.004).

Post-hoc comparisons showed that T2app was significantly increased only in symptomatic TTR-FAP (103.92ms±6.4) vs. asymptomatic gene-carriers (79.14ms ±1.8; p=0.012) and vs. controls (84.08ms±2.54; p=0.003), but not between asymptomatic gene-carriers and controls (p=0.783).

Conclusion

For the first time, we were able to prove that alterations of the evaluated quantitative markers were highly specific: Asymptomatic carrier-status and symptomatic disease were both closely associated with a strong increase of proton-spin-density, while a significant increase of the T2-relaxation-time was found only in symptomatic TTR-FAP, but not in asymptomatic carriers. These findings suggest that proton-spin-density is more sensitive for the detection of early or even subclinical nerve-lesions, while T2app may serve to specifically differentiate increasing disease severity in already symptomatic TTR-FAP.

¹University of Heidelberg, Department of Neuroradiology, 69120, Heidelberg, Germany

Full list of author information is available at the end of the article

Authors' details

¹University of Heidelberg, Department of Neuroradiology, 69120, Heidelberg, Germany. ²University of Heidelberg, Department of Neurology, 69120, Heidelberg, Germany. ³University of Heidelberg, Medical Department V (Amyloidosis Center), 69120, Heidelberg, Germany. ⁴University of Heidelberg, Medical Department III (Amyloidosis Center), 69120, Heidelberg, Germany.

Published: 2 November 2015

doi:10.1186/1750-1172-10-S1-O14

Cite this article as: Kollmer *et al.*: Quantitative MR-neurographic parameters can determine and specify nerve injury in amyloid related polyneuropathy. *Orphanet Journal of Rare Diseases* 2015 **10**(Suppl 1):O14.

**Submit your next manuscript to BioMed Central
and take full advantage of:**

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

